Allen Gao, M.D., Ph.D.

Allen Gao, M.D., Ph.D.



Urologic Oncology





  • Professor
  • Ralph de Vere White Professor and Director of Urologic Research
  • Co-Leader, Prostate Cancer Program

Clinical Interests

Dr. Gao?s research interests focus on understanding molecular mechanisms associated with progression of castration-resistant prostate cancer and metastasis to bone with the goal of identification of potential therapeutic targets for prostate cancer. Particular emphasis includes microRNAs, aberrant androgen receptor activation by cytokines and transcriptional factors such as Stat3 and NF-kB, selenium chemoprevention and therapy, and targeting cell signaling pathways (AR, IL-6 and Stat3) in prostate cancer. Dr. Gao?s lab was among the first to find that selenium regulates androgen signaling, find that IL-4 activates androgen receptor mediated by NF-kB and Stat6, made the discovery that IL-6 signaling in prostate cancer involves Stat3, and defined Stat3 and NF-kB interactions in prostate cancer. Dr. Gao has published over 60 peer-reviewed articles on the area of prostate cancers. Dr. Gao has served numerous NCI, DOD, and VA merits, and ACS review panels including SPORE and PPG study sections.



Center/Program Affiliation

UC Davis Comprehensive Cancer Center


M.D., Sichuan Medical College, Chengdu, Sichuan, 1985

Ph.D., University of Texas, Houston, School of Public Health, Houston, Texas, 1995


John Hopkins University School of Medicine, Baltimore, Maryland, 1998

Professional Memberships

Ad Hoc Member for NIH DMP Study Section

Ad Hoc member for NIH Metabolic Study Section

Ad Hoc reviewer for NIH Tumor Microenvironment study section

Editorial Board, The Prostate

Member, ACS TBE study section

NCI Special Emphasis Panel, Cancer Prognosis and Prediction

Reviewer Committee Member, O?Brien Urology Center Program

Scientific Reviewer Panel, DOD Prostate Cancer Program, Breast Cancer Program

Honors and Awards

Ralph deVere White Endowed Professor of Urologic Research, University of California, Davis, 2008

First prize award, AUA Assay Contest, Gleave, M., Hsieh JT, Gao A.C. Von Eschenbach A.C., and Chung L.W.K. Acceleration of Human Prostate Cancer Growth in vivo by Factors Produced by Prostate and Bone Fibroblasts., 1991

Select Recent Publications

Zhu YZ, Liu, C.F., Nadiminty, N., Lou, W., Tummala, R., Evans, C.P., Gao, A. C. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther  2013 12 (9): 1829-36.

Nadiminty N, Tummala R, Lou W, Zhu YZ, Evans CP, Gao AC. NF-kB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants.  Molecular Cancer Ther 2013 12 (8): 1629-37.

Tummala R, Nadiminty N, Lou W, Zhu YZ, Chen HW, Evans CP, Gao AC. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. American J. of Pathology. 2013 183 (1): 288-95.

Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012 Jan 6;287(2):1527-37. Epub 2011 Nov 28.

Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011 Feb;2(2):151-9.

Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 2010 Apr 15;70(8):3309-19. Epub 2010 Apr 13.

Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther. 2009 Mar;8(3):665-71. Epub 2009 Feb 24.

Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res. 2009 Aug 1;15(15):4815-22. Epub 2009 Jul 28.

Nadiminty N, Chun JY, Lou W, Lin X, Gao AC. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate. 2008 Dec 1;68(16):1725-33.

Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther. 2007 Sep;6(9):2572-80.

Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, and Gao AC. Stat3 activation of NF-kB p100 processing involves CBP/p300 mediated acetylation. Proc Natl Acad Sci USA, 103 (19): 7264-7269, 2006